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Background
In 1997, a 15-mer mimotope of MAb IgG1b12, a potent
virus-neutralizing and broadly reactive anti-HIV-1 MAb,
was identified through phage display technology. Mimo-
topes find a variety of applications in protein engineering,
identification of protein functions and vaccine design.
However, because of the peptide's relatively small size, it
may not be immunogenic on its own. Our group has
designed and developed homogeneous and structurally
well-defined synthetic multivalent mimotope constructs
of MAb IgG1b12 as vaccine candidates. One of the con-
structs involves conjugation with a known potent, syn-
thetic, ''universal'' HTL epitope composed of a 13-mer
peptide, PADRE, as an immunogenic carrier.
Methods
IgG1B12 mimotope was prepared using microwave-
assisted solid-phase peptide synthesis (SPPS) using a ver-
satile hydrophilic base-labile hydroxyl-terminated resin,
tentagel HMBA. The unique ester linkage with the peptide
allows for orthogonal amino acid side-chain deprotection
and peptide cleavage from the resin using various nucle-
ophiles to yield peptides with a variety of functional
groups at the C-terminus. This orthogonal property allows
for on-bead screening studies of deprotected peptide on
the resin for future studies. The mimotope was function-
alized with different linkers via microwave-assisted solid-
phase amide coupling for multimerization experiments. A
similar strategy was applied for the preparation of PADRE
peptide and its functionalized counterparts.
Results
The different constructs developed involve chemically
conjugating functionalized mimotope and PADRE using a
scaffold with various strategies such as click chemistry,
solution and solid phase amide coupling for multivalent
presentation. Constructs were purified by reversed phase
HPLC and characterized by SDS-PAGE and HRMS.
Conclusion
Fully synthetic multivalent mimotope constructs were
designed, prepared and characterized. The versatility of
chemical synthesis allows for further modification for
structure-bioactivity relationship. These constructs are
potential platforms for HIV vaccine development and
have advantages in terms of safety, homogeneity and
large-scale production.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P335 doi:10.1186/1742-4690-6-S3-P335
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P335
© 2009 Go et al; licensee BioMed Central Ltd. 